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Response of the kidney to furosemide. II. Effect of captopril on sodium
balance. We investigated the role of the renin-angiotensin-aldosterone
(RAA) system during furosemide (F) administration. The effects of
adding captopril (C) (25 mg 6 hr') to F (40 mg daily for 3 days) were
studied in six normal subjects equilibrated to a daily sodium (Na) intake
of 270 mmoles. Without C, F produced a marked natriuresis but Na+
excretion fell sharply between drug doses. This resulted in neutral Na
balance (+22 58 mmoles .3 days': mean SE). Plasma angiotensin
(All) and aldosterone (Aldo) rose, but mean blood pressure (MBP) was
unaltered. C abolished the F-induced increases in All and Aldo but did
not modify the pattern of Na+ excretion. Na+ balance remained
neutral (+42 54 mmoles 3 days'). With C alone, Na+ balance was
positive (+ 110 30 mmoles .3 days1; P <0.02). In protocols C alone
and F + C, MBP fell by a comparable amount. F alone and F + C
increased plasma norepinephrine and prostaglandin E2 metabolite;
these did not change with C alone. In conclusion, activation of the RAA
system by F is not essential for the compensatory increase in Na+
reabsorption that maintains Na+ balance after F. Sympathetic nervous
system activation or changes in prostaglandin E2 release may contribute
to the increased Na+ reabsorption that follows the acute natriuresis
induced by F.
Rponse du rein au furosémide. II. Effet du captopril sur le bilan du
sodium. Nous avons étudié le role du système rénine-angiotensine-
aldostérone (RAA) pendant l'administration de furosémide (F). Les
effets de l'adjonction de captopril (C) (25 mg 6 hr') a F(40 mg par jour
pendant 3 jours) ont été étudiés chez six sujets normaux equilibres avec
un apport sodé (Na)journalier de 270 mmoles. Sans C, F a entrainé une
natriurèse marquee mais l'excrétion de Na+ s'est effondrée entre les
administrations du médicament. Cela a entraine un bilan de Na nul (-I-
22 58 mmoles 3 jours', moyenne + SE). L'angiotensine (All) et
l'aldostérone (Aldo) plasmatiques ont augmenté, mais La pression
artérielle moyenne (MBP) était inchangée. C a aboli les augmentations
induites par F de All et d'Aldo, mais n'a pas module l'aspect de
l'excrCtion de Na. Le bilan de Na est restée nul (+42 54 mmoles 3
jours). Avec C tout seul, le bilan Na était positif (+ 110 30 mmoles 3
jours; P < 0.02). Dans les protocoles C tout seul et F + C, MBP a
chute de facon comparable. F tout seul et F + C ant augmenté Ia
noradrénaline plasmatique et le métabolite de Ia prostaglandine E2;
ceux-ci n'ont pas change avec C tout seul. En conclusion l'activation du
système RAA par F n'est pas essentielle pour l'augmentation compen-
satrice de Ia reabsorption de Na qui maintient la balance de Na après F.
L'activation du système nerveux sympathique ou des modifications du
relargage de prostaglandine E2 pourraient contribuer a l'augmentation
de reabsorption de Na+ qui suit Ia natriurèse aiguë induite par F.
Although furosemide (F) causes a substantial acute salt loss,
repeated daily doses do not induce a negative sodium (Na+)
balance unless Na+ intake is restricted [1, 21. We found that
maintenance of Na+ balance was due to reduced sodium
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excretion (UNaV) in the periods between diuretic doses. This
was accompanied by activation of the renin-angiotensin-aldos-
terone (RAA) system which could, therefore, be responsible for
Na+ retention in the period between F doses.
In the present study, we have investigated the role of RAA
system activation in the compensatory increase in Na+ reab-
sorption following F by use of the angiotensin-converting
enzyme inhibitor, captopril. The role of other hormonal sys-
tems was assessed by measurement of plasma epinephrine,
norepinephrine, dopamine, and the metabolites of prostaglan-
din E2, and prostacyclin. In addition, the rate of F excretion
was measured to determine whether C, by causing changes in
renal blood flow [3], altered the kinetics of F.
Methods
Six normal subjects were studied for 8 days on three different
occasions, separated by a period of at least 3 weeks, This study
was approved by the Human Subjects Committee of the
Brigham and Women's Hospital, Boston, Massachusetts, and
the subjects gave informed consent. During these experimental
protocols, the subjects ate a regulated diet containing a daily
intake of 20 mmoles of Na+ and 70 to 80 mmoles of potassium
(K+). They received meals at 6 to 7A.M., 12 to 1 P.M., and 7 to
8 P.M. Each meal was supplemented with five, l-g sodium
chloride tablets to give a daily Na+ intake of 270 mmoles. Fluid
intake was unrestricted. Subjects continued their usual daily
activities except that strenuous exercise was proscribed. In
each study, the subjects ate the diet for 3 days to achieve
equilibration of Na+ and K+ intake and output before any
measurements were made. Thereafter, urine samples were
collected in 6-hr aliquots. For the next 2 days (days 4 and 5), the
subjects did not receive drugs, and their urine samples were
analyzed to determine "basal" levels of UNaV. On days 6 to 8,
subjects received furosemide alone (F), furosemide plus capto-
pril (F + C) or captopril alone (C). During the F and F + C
protocols, 40 mg of furosemide were given intravenously on the
mornings of days 6 and 8 and orally on day 7. During the F + C
protocol, 25 mg of captopril were given 1 hr before the first dose
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Fig. 1. Values for 6 hourly rates of sodium excretion for the F and F + C
protocols. Each rate shown for the control days represents the average
value for the corresponding periods during days 4 and 5 of each
protocol. Furosemide was given at the start of each subsequent day
(panels A and B); captopril was given orally every 6 hours beginning on
day 6 (panel B). The dashed horizontal line represents the average rate
of Na+ excretion determined during the control days, and the solid and
diagonal shading represent the differences between the measured Na+
excretion and this basal rate of excretion.
of furosemide; subsequent doses of 25 mg were given orally
every 6 hr until completion of the study. During the C protocol,
captopril was given in an identical manner but without furose-
mide. Standing blood pressure (BP) and heart rate (HR) were
determined after equilibration to the regulated diet on day 5 and
immediately before and 5 hr after each intravenous dose of
diuretic and at the corresponding part of the day on the C alone
protocol. At 7:30 A.M. on days 6 and 8 of each study, an
intravenous cannula was inserted. After 45 mm of quiet sitting,
blood was drawn for hormone and electrolyte levels. Immedi-
ately thereafter on the F and F + C protocols, furosemide was
given intravenously, and further blood samples were obtained
after 5 hr. During the C alone protocol, the same quantities of
blood were drawn at comparable times of the day. The first
plasma sample was taken 1 hr after the oral dose of captopril
and the second sample 5 hr later,
Plasma samples were assayed for renin activity (PRA),
angiotensin II (All), aldosterone (Aldo), epinephrine (E), nor-
epinephrine (NE), dopamine (DA), and the metabolite of pros-
taglandin E2 (PGE-M) and prostacyclin (PG6-keto-Fia) by
previously described methods [4—7].
Urine samples were frozen for subsequent determinations of
Na+, K+, creatinine, and furosemide concentrations. Furose-
mide was assayed by a high-performance liquid chromatogra-
phy technique after extraction into ether [8]. The standard
curve was linear over the range of samples measured, with
recovery averaging 96% 3% (mean SEM).
Statistical analyses were performed by paired t tests to assess
within-subject variation. Results were judged to be statistically
significant at P < 0.05. Mean values SEM are presented.
Results
Figure 1 shows the pattern of UNaV during the F and F + C
studies. There were no statistically significant differences in the
average basal rate of UNaV (--- 70 mmoles 6 hr') during the
three experimental protocols. On each day when F was given,
UNaV increased abruptly above basal levels; the magnitude of
the acute loss of Na+ is indicated by solid shading in Figure 1.
However, in the ensuing 18-hr periods UNaV decreased well
below basal levels resulting in positive Na+ balance during this
compensation period (indicated by horizontal shading). It is
apparent from Figure 1 that this pattern of an acute increase in
UNaV followed by a prolonged reduction in UNaV was repro-
duced in precisely the same manner on each of the 3 days when
the subjects were given C in addition to F. Importantly, with C
the acute Na+ losses in the 6 hr after F were balanced exactly
by the reduced UNaY in the periods between diuretic doses and,
as with F alone, this resulted in neutral Na+ balance.
The acute increase in fractional excretion of sodium (FENa) in
the 6 hr following F above that of the preceding 6 hr was 2.5
0.3% and 2.3 0.8% on days 6 and 8 of F alone. These values
were not significantly different from those on the corresponding
days of F + C (2.8 0.4% and 2.6 0.6%).
The time course of the acute natriuresis following intrave-
nous administration of F on days 6 and 8 is illustrated in Figure
2. After F + C administration, UN5V reached the same peak
level and decreased with the same time course as with F alone.
As shown in Figure 1, the increase in UNaV in the 6 hr after F
was given by mouth on day 7 tended to be somewhat greater
after C, but this difference was not significant statistically.
Sodium balance was calculated as the difference between Na
intake and excretion. The cumulative balance during 3 days of
drug administration is shown in Figure 3. Cumulative Na+
balance after 3 days of F was neutral. On C alone, there was
some Na+ retention during the 3-day period so that the
cumulative Na+ balance was positive (+ 110 30 mmoles; P <
0.02). Despite positive Na+ balance produced by C, the addi-
tion of F to C led to neutral Na+ balance. There were no
statistically significant changes in body weight, hematocrit,
plasma Na, K, or protein concentrations over the 3 days of drug
administration with any protocol.
The effectiveness of the C blockade of the RAA system's
response to F is illustrated in Figure 4. Acute changes in
hormone levels were similar on days 6 and 8, and therefore
were combined. The 270 mmoles Na+ intake led to low
baseline values of PRA, All, and Aldo which were not signifi-
cantly different between the protocols before drug administra-
tion. On days 6 and 8 of the F alone protocol, there was a rise in
both plasma A!! and Aldo 5 hr after the diuretic was adminis-
tered, but these changes were abolished entirely by C. PRA also
increased 5 hr after F was given on days 6 and 8; when C was
given with F, the rise in PRA was significantly higher than on F
alone (P < 0.01). C alone also led to the expected rise in PRA
and there was a small, but significant, rise in plasma A!!
although Aldo levels tended to fall. Changes in the plasma
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Fig. 2. Renal sodium excretion during the 210
mm following intravenous administration of
furosemide (40 mg) in the presence (open
squares) or absence (closed squares) of
captopril. Values shown are mean Sc on
days 6 and 8.
Blood pressure Heart rate
Day 6 Day 8 Day 6 Day 8
Before After Before After Before After Before After
Furosemide 94.0 4.6
Captopril 94.6 3.0
Furosemide + Captopril 95.9 3.4
90.1 2.4
81.4 3.4"
90.3 4.9
91.5 2.6
86.3 3.4"
83.3 3.1"
96.4 3.7
80.1 4Øb
83.8 3.1"
79.7 4.1
90.0 1.5
86.0 3.7
84.3 7.7
90.5 2.9
93.5 5.5
78.5 4.9
89.8 2.8
95.3 4.0
81.7 5.4
92.7 5.1
94.3 3.9
a Mean arterial pressure and heart rate were measured in the patients while standing on days 6 and 8 before and after furosetnide administration
for F and C + F protocols. Values also were obtained at the corresponding time of day during the C alone protocol. Values are expressed as mean
SCM.
b P < 0.02.
P < 0.05.
levels of NE, DA, and PGE-M produced by the drugs were
similar on days 6 and 8, and therefore were combined as before
and are presented in Figure 5. Basal levels of plasma NE did not
differ among the three protocols (F, 218.0 30.4; F + C, 268.3
48.5; C, 236.5 36.8 pg m11). Plasma NE increased acutely
after F (+ 137 50 pg m1'; P < 0.05), and with concurrent C
administration (+91 20 pg ml; P < 0.01). With C alone,
plasma NE did not change acutely nor over the 3 days of C
administration. Plasma E changed neither acutely nor over the 3
days of any of the protocols. However, basal levels of DA (19.9
3.5 pg mr') increased significantly following C alone (+7.3
2.2 pg m1'; P < 0.01). There were no consistent acute
changes in plasma DA during either the F or F + C protocols.
There was a rise in PGE-M both with F alone (+ 124 51 pg
ml; P < 0.05) and with F + C (+ 152 58.6; P < 0.05). As
shown in Figure 5, there was a comparable rise in PGE-M with
C alone, but the greater variability precluded a statistically
significant change (+85 54.8). There were no significant
changes in plasma levels of the prostacyclin metabolite, PG6-
keto-F1, in any protocol. Thus, acute volume depletion with F
was associated with significant increases in plasma NE and
PGE-M, and these changes were not modified by concurrent
administration of C. With C alone, there was a tendency for
PGE-M and DA to rise but NE was unchanged.
The basal value of creatinine clearance was 103.5 12.3
mI/mm/i .72 m2 and did not vary among the protocols. Creati-
nine clearance tended to fall following the F-induced diuresis,
but it returned to basal levels after 6 hr on F + C and after 12 hr
on F alone. Neither change from basal levels was significant
statistically.
The rates of F excretion during the F and F + C protocols are
shown in Figure 6. In both protocols, F excretion was maximal
in the first 30 mm after the drug was given and declined in an
exponential manner thereafter. C did not change the peak rate
or time course of F excretion.
The average values for MBP and HR are shown in Table 1.
Considering first the acute changes produced 6 hr after drug
administration, there were no significant changes in MBP or HR
on either days 6 or 8 with F alone or F + C. During C alone, the
first dose decreased MBP significantly (—13.2 3.8 mm Hg; P
<0.02). This occurred without any accompanying tachycardia.
Considering the changes occurring over 3 days of drug adminis-
tration, MBP and HR were unchanged with F alone. However,
by the morning of day 8 of the F + C protocol, MBP had
decreased (—12.8 4.1 mm Hg; P < 0.05) by an amount similar
to that during C alone, The HR did not change significantly
from pre-drug values on any protocol.
Discussion
Effects offurosemide and captopril on Na+ balance
A decline in UNaV accompanies extracellular fluid volume
(ECV) depletion whether produced acutely by hemorrhage or
more chronically by a low-salt intake. Furthermore, renin
secretion increases early in the course of hemorrhage or dietary
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Table 1. Blood pressure and heart rate response
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Day6 Day6-i-7 Day6+7+8
Fig. 3. Cumulative sodium balance (mean SEM) during eachprotocol.
Abbreviations: F, furosemide alone protocol; C, captopril alone proto-
col; F + C, captopril plus furosemide protocol.
sodium chloride deprivation leading to a rise in plasma All and
Aldo levels. There is a close inverse relationship between
dietary salt intake and activation of the RAA system [9].
Aldosterone and All can increase renal Na+ reabsorption.
The administration of Aldo or All to adrenalectomized animals
leads to a dose-related decrease in UNaV [101. Indeed, pro-
longed infusions of angiotensin II in subpressor doses [11, 12] or
repeated administration of mineralocorticosteroids [13] to con-
scious animals or humans causes a progressive retention of
Na+ until a new steady-state of Na+ balance is achieved with
an expanded ECV.
Experiments using pharmacologic blockade of the actions of
All or Aldo also suggest that the RAA axis is critically
important in the renal response to ECV depletion. Thus,
administration of spironolactone to normal subjects ingesting a
low-salt diet doubled UNaV [141. In addition, C given to normal
subjects whose RAA system was stimulated by a low Na+
intake also increased UNaV [3, 15]. Infusion of either C or the
All receptor antagonist, saralasin, into one renal artery of salt-
depleted dogs led to an ipsilateral increase in UNaV [16, 17].
Even in subjects who are "salt-replete," angiotensin-convert-
ing enzyme blockade resulted in significant reductions in sys-
temic BP and renal vascular resistance [3, 151.
In both the F and F + C protocols, the subjects lost
approximately 160 mmoles of Na+ (equivalent to about 1 liter
of ECV) on each occasion that they received F. As shown in
Figure 4, during F alone this resulted in an immediate increase
in PRA accompanied by a 130% increase in plasma All and a
71% increase in plasma Aldo. Thus, F activated the RAA
system despite the liberal dietary Na+ intake. Although this
probably was the result of the decreased ECV, loop diuretics
have been shown to release renin independently of ECV
depletion [18, 19].
We showed recently that the acute natriuresis produced by F
was succeeded by a prolonged period of Na+ retention between
drug doses [21. Kahn et al [1] found that dogs given 40 mg of F
three times a day while they were ingesting a high-salt diet
maintained a neutral Na+ balance. The physiologic basis for
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these observations is unknown. In the present study, we
prevented the rise in plasma All and Aldo after F and as shown
in Figure 1, there was no change in the pattern of UNaV on any
of the 3 days on which F was administered. Moreover, the
maximal rate and subsequent pattern of Na+ excretion follow-
ing the diuretic were unchanged by C.
It is important to consider why C did not modify the acute
natriuretic response to the diuretic or the ensuing period of
Na+ conservation. It is clear from Figure 4 that the dose of C
was adequate to suppress generation of All and release of Aldo
produced by F. A 25 mg dose of C has been shown previously to
produce an almost complete blockade of angiotensin-converting
enzyme for 6 hr in humans [3, 201. We monitored UNSV hourly
for the 6-hr period after F was given and found that it did not
increase although a second dose of C was taken 4 hr after the
diuretic. Thus, C did not increase UNaV even at the time of
maximal ECV depletion.
Sodium excretion following F is partially dependent on the
delivery of the drug to its active site in the tubular lumen. As C
increases renal blood flow in normal humans, it may have
altered the natriuretic response to the diuretic [21]. Neverthe-
less, as shown in Figure 6, neither the peak rate nor the overall
pattern of renal F excretion were modified by C. Consequently,
the ratio of UNaV to UFV, which has been used to indicate
diuretic efficacy [22], was unaffected by C.
Captopril has other actions besides the inhibition of All
formation. Although C can cause a rise in bradykinin levels,
there is little evidence that this creates changes in renal function
[3]. In a dose equivalent to that which we used, C can increase
plasma PGE-M in humans, which correlates with the hypoten-
sive action of C in subjects receiving a liberal salt intake [7].
The effects of C on PGE2 release are relevant to the present
study because F itself is reported to release PGE2 from the
kidney, and studies using cyclo-oxygenase inhibitors suggest
that PGE2 may mediate some of the increase in renal blood
flow, renin release, and natriuresis that occur with F [231.
Although the rise in PGE-M on C alone did not reach statistical
significance, the average increase was actually higher than that
previously reported to occur in normal subjects given C [7].
PGE-M also rose significantly following the acute diuresis
during the F and F + C protocols, and it is conceivable that
enhanced PGE2 release by F and C may have contributed to the
pattern of Na+ retention. However, prostaglandins are normal-
ly considered to be natriuretic [24].
Of interest was the finding that C caused a positive Na+
balance and increased plasma DA levels. Dopamine reduces
renal and splanchnic vascular resistance and therefore could
contribute to the vascular actions of C. However, the observed
change in plasma DA, although statistically significant, was
small and its physiologic importance is not clear [25].
What mediated the compensatory fall in UNaV following F?
The present experiments exclude the necessity for activation of
the RAA system. Although small changes in GFR [26] and
therefore, the filtered load of Na+ may not have been detected,
there were no significant changes in creatinine clearance, and
studies with the isolated dog kidney [27] or intact animals [28]
have indicated that modest changes in GFR are not important
determinants of UNaV.
The autonomic nervous system has been implicated in the
regulation of Na+ reabsorption during salt restriction in pa-
tients with autonomic failure [29, 30], in normal subjects given
sympatholytic drugs [31] and in rabbits given these drugs or
subjected to renal denervation [321. Renal denervation in ani-
mals blunts the decrease in renal blood flow and UNSV after
hemorrhage, suggesting that renal sympathetic nerves are im-
portant in both the acute and prolonged responses to ECV
contraction [33]. The actions of the sympathetic nervous sys-
tem on Na+ reabsorption are mediated partially by reflex
stimulation of the RAA system and a direct action of catechol-
amines on tubular Na+ reabsorption [34]. We observed a
consistent rise in plasma NE levels following F in confirmation
of previous reports [35]; this was unaffected by administering C.
This suggests that F may have activated the sympathetic
nervous system which could have mediated some of the de-
crease in UNaV that followed the diuretic. On the other hand,
the effects of diuretics on NE disposition are unknown.
Changes in plasma NE levels reflect not only sympathetic
nervous system activity, but also reuptake of neurotransmitters
into sympathetic nerves, hepatic metabolism, and renal elimina-
tion. Without further studies, it is difficult to determine the
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precise role of the sympathetic nervous system in these
protocols.
Effects offurosernide and captopril on blood pressure
One factor that may have contributed to Na+ retention with
C was the fall in BP. When C is given to animals during RAA
stimulation by inferior vena cava constriction [361 or to human
subjects with congestive cardiac failure [37], UNaV increases
only transiently until a new equilibrium is achieved. Limitation
of the natriuretic effect of C has been ascribed to an accompa-
flying fall in BP; this also may explain why C does not increase
UNaV routinely during salt deprivation [15, 38]. Indeed, Hall et
al [17] found that a fall in BP of only 3 mm Hg abolished the
increase in UNaV produced by saralasin in salt-restricted dogs.
In our study, F alone did not lower MBP despite loss of
approximately 1 liter of ECV while C reduced BP when given
alone and when given with F over the 3 days of the protocol.
This hypotensive action of C may have balanced any natriuretic
effect of RAA blockade and could account for the development
of a positive Na+ balance when C was given alone. This
confirms previous reports [3, 15] that C alone causes an
immediate fall in BP despite a liberal salt intake. Interestingly,
however, when C was given with F, the acute hypotensive
action of C was abolished. This apparent paradox may be
explained by activation of the sympathetic nervous system by
F, as evidenced by the acute rise in plasma NE on both F and F
+ C. In contrast, C alone did not increase NE levels or HR and
the MBP fell [35, 39, 40]. Captopril alone did cause a small rise
in plasma DA and PGE-M, both of which could have contribut-
ed to the acute hypotensive response seen with the drug.
A diuretic can potentiate the hypotensive effect of C in
patients with hypertension, and we found that C + F given for 3
days reduced the MBP of normal subjects [41—44]. However,
we found that the fall in BP with C was not potentiated by F,
perhaps because F did not cause a negative Na+ balance at this
level of salt intake. Indeed, Ram, Garrett, and Kaplan [45]
found little effect of F in reducing the BP of hypertensive
subjects even when F was given twice daily unless dietary Na
was restricted. If our study is relevant to the treatment of
hypertension, the data indicate that dietary salt must be restrict-
ed to ensure that negative Na+ balance develops with F even
during angiotensin-converting enzyme blockade.
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